http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2013-12-13 13:34:132013-12-17 09:53:52Ponencias de la I Jornada de Vacunación en enfermería. Vitoria-Gasteiz
The purpose of this resolution is to update the resolution to include use of a meningococcal vaccine recently licensed for use in a new age group and to simplify the language within the recommended vaccination schedule and intervals section.
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2013-12-04 14:09:412015-04-29 16:08:42ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES VACCINES FOR CHILDREN PROGRAM VACCINES TO PREVENT MENINGOCOCCAL DISEASE
Antimicrobial resistance is one of our most serious health threats. Infections from resistant bacteria are now too common, and some pathogens have even become resistant to multiple types or classes of antibiotics (antimicrobials used to treat bacterial infections). The loss of effective antibiotics will undermine our ability to fight infectious diseases and manage the infectious complications common in vulnerable patients undergoing chemotherapy for cancer, dialysis for renal failure, and surgery, especially organ transplantation, for which the ability to treat secondary infections is crucial.
When first-line and then second-line antibiotic treatment options are limited by resistance or are unavailable, healthcare providers are forced to use antibiotics that may be more toxic to the patient and frequently more expensive and less effective. Even when alternative treatments exist, research has shown that patients with resistant infections are often much more likely to die, and survivors have significantly longer hospital stays, delayed recuperation, and long-term disability. Efforts to prevent such threats build on the foundation of proven public health strategies: immunization, infection control, protecting the food supply, antibiotic stewardship, and reducing person-to-person spread through screening, treatment and education.
Dr. Tom Frieden, MD, MPH
Director, U.S. Centers for Disease Control and Prevention
Meeting the Challenges of Drug-Resistant Diseases in Developing Countries
Committee on Foreign Affairs Subcommittee on Africa, Global Health, Human Rights,
and International Organizations
United States House of Representatives
April 23, 2013
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2013-11-04 20:03:252013-11-04 20:15:37ANTIBIOTIC RESISTANCE THREATS in the United States, 2013
Although most persons who become infected with influenza viruses will recover without sequelae, influenza can cause serious illness and death, particularly among persons aged ≥65 years and <2 years and those with medical conditions that confer high risk for complications from influenza (1–4). During 30 seasons from the 1976–77 season through the 2005–06 season, estimated influenza-associated deaths ranged from 3,000 to 49,000 annually (4).
Annual influenza vaccination is the primary means of preventing influenza and its complications. There are many types of influenza vaccines, and the naming conventions have evolved over time (Box). Routine annual influenza vaccination for all persons aged ≥6 months who do not have contraindications has been recommended by the CDC and CDC’s Advisory Committee on Immunization Practices (ACIP) since 2010 (5 ). This report provides updated recommendations and guidance for vaccination providers regarding the use of influenza vaccines for the 2013–14 season.
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2013-09-20 13:37:092015-05-21 18:26:38Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2013–2014
La enfermedad neumocócica invasiva (ENI) supone un grave problema de salud entre los adultos con determinadas condiciones y patologías de base, entre los que destacan los inmunodeprimidos y algunos inmunocompetentes, que les hacen más susceptibles a la infección y favorecen cuadros de mayor gravedad y peor evolución. Entre las estrategias para prevenir la ENI se encuentra la vacunación, aunque las coberturas vacunales en este grupo son más bajas de lo deseable. Actualmente, existen 2 vacunas disponibles para el adulto. La vacuna polisacárida (VNP23), que se emplea en mayores de 2 años de edad desde hace décadas, es la que mayor número de serotipos (23) incluye, pero no genera memoria inmunitaria, los niveles de anticuerpos disminuyen con el tiempo, provoca un fenómeno de tolerancia inmunitaria y no actúa sobre la colonización nasofaríngea. La vacuna conjugada (VNC13) puede emplearse desde lactantes hasta la edad adulta (la indicación en mayores de 18 años ha recibido la aprobación de la Agencia Europea del Medicamento en julio de 2013) y genera una respuesta inmunitaria más potente que la VNP23 frente a la mayoría de los 13 serotipos en ella incluidos. Las 16 Sociedades Científicas más directamente relacionadas con los grupos de riesgo para padecer ENI han trabajado en la discusión y elaboración de una serie de recomendaciones vacunales basadas en las evidencias científicas respecto a la vacunación anti-neumocócica en el adulto con condiciones y patología de base que se detallan en este documento. Se trata de un documento «vivo» que seguirá actualizándose ante nuevas evidencias científicas disponibles.
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2013-09-13 12:26:592013-09-13 12:26:59Consenso sobre la vacunación anti-neumocócica en el adulto con patología de base
Utilizamos cookies propias y de terceros para mejorar nuestro servicio y mostrar contenido relacionado con tus preferencias mediante el análisis de los hábitos de navegación.<br /> Si continúas navegando, consideramos que aceptas su uso. Más información
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.